Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes  

作　　者：Hong-wei GAO Chao XIE Hai-ning WANG Vu-jing LIN Tian-pei HONG 

机构地区：[1]Department of Endocrinology, Peking University Third Hospital, Beijing 100083, China

出　　处：《Acta Pharmacologica Sinica》2007年第4期534-539,共6页中国药理学报（英文版）

基　　金：grants from the National"211 Project"Peking University EBM Group(№ 93000-246156070);the Natural Science Foundation of Beijing City(№ 7062067);the Major State Basic Research Development Program of China(№ 2006CB503900)

摘　　要：Aim： To investigate the acute and chronic effects of nateglinide versus acarbose on plasma asymmetric dimethylarginine （ADMA） levels and lipid profiles in patients with newly-diagnosed type 2 diabetes. Methods： A crossover trial of nateglinide and acarbose was conducted on 16 drug-naive patients with newlydiagnosed type 2 diabetes during a total period of 9 weeks. Plasma glucose, serum insulin, free fatty acids （FFA）, lipids and lipoproteins, and plasma ADMA were measured. Results： The efficiencies of a single dose of nateglinide （120 mg） and acarbose （50 mg） for lowering postprandial hyperglycemia were similar. Compared to acarbose, nateglinide significantly increased postprandial insulin release after a standard meal test in patients with type 2 diabetes. Nateglinide acutely decreased postprandial 120 min FFA concentrations and 240 min ADMA levels more significantly than acarbose. The fasting high-density lipoprotein cholesterol level increased and the low-density lipoprotein cholesterol level decreased significantly, but the fasting levels of triglycerides, total cholesterol, and ADMA were unchanged after 4 weeks of treatment with nateglinide. Acarbose did not affect fasting lipid profiles or the ADMA levels after 4 weeks of treatment. Conclusion： These results suggest that the reduction of postprandial FFA and ADMA concentrations induced by nateglinide may be associated with the partial restoration of early-phase insulin secretion and may impart a cardiovascular advantage in comparison with acarbose.Aim： To investigate the acute and chronic effects of nateglinide versus acarbose on plasma asymmetric dimethylarginine （ADMA） levels and lipid profiles in patients with newly-diagnosed type 2 diabetes. Methods： A crossover trial of nateglinide and acarbose was conducted on 16 drug-naive patients with newlydiagnosed type 2 diabetes during a total period of 9 weeks. Plasma glucose, serum insulin, free fatty acids （FFA）, lipids and lipoproteins, and plasma ADMA were measured. Results： The efficiencies of a single dose of nateglinide （120 mg） and acarbose （50 mg） for lowering postprandial hyperglycemia were similar. Compared to acarbose, nateglinide significantly increased postprandial insulin release after a standard meal test in patients with type 2 diabetes. Nateglinide acutely decreased postprandial 120 min FFA concentrations and 240 min ADMA levels more significantly than acarbose. The fasting high-density lipoprotein cholesterol level increased and the low-density lipoprotein cholesterol level decreased significantly, but the fasting levels of triglycerides, total cholesterol, and ADMA were unchanged after 4 weeks of treatment with nateglinide. Acarbose did not affect fasting lipid profiles or the ADMA levels after 4 weeks of treatment. Conclusion： These results suggest that the reduction of postprandial FFA and ADMA concentrations induced by nateglinide may be associated with the partial restoration of early-phase insulin secretion and may impart a cardiovascular advantage in comparison with acarbose.

关 键 词：NATEGLINIDE ACARBOSE free fatty acids asymmetric dimethylarginine 

分 类 号：R977.15[医药卫生—药品]